Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome. Rein L, Calero K, Shah R, Ojielo C, et al. Crit Care Med 2022;50:1701-1713.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rein L, Calero K, Shah R, Ojielo C, et al. Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome. Crit Care Med 2022;50:1701-1713.
PMID: 36226977